List of Active ICON Protocols

1.    A Phase II study of Gemcitabine as 4 hour infusion with carboplatin in inoperable stage III and IV NSCLC (Protocol No: ICON/ LUNG/ 0105) Status:

2.    Comprehensive Management for patients with Chronic Myeloid Leukemia (Protocol TMC/CML/MO-0401; Version Date 20 April 2004) – a phase II feasibility and tolerability study. Status: Ongoing

3.    Combination Chemotherapy for MM (Protocol No: ICON/Hematol-MM/0306) Status: Ongoing

4.    A phase II b RCT of Neo adjuvant chemotherapy comparing Paclitaxel, Ifosfamide and Cisplatin with Paclitaxel, Cisplatin and 5-FU in patients with locally advanced head & neck cancer. (Protocol No: ICON/H&N/0601) Status: Completed

5.    An open label, multicentre phase I/II dose escalating study of Pablocan (NPB001-05) in patients of chronic myeloid leukemia who have demonstrated resistance / intolerance to the local prevailing standard of care.(Protocol No: ICON/CML/0701) Status: Ongoing

6.    An Observational Study of Pegylated Liposomal Doxorubicin and Carboplatin in Patients with Platinum Sensitive Epithelial Relapsed Ovarian Cancer. (Protocol No: ICON/Ovary/0703) Status: Ongoing

7.    A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine)  (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) Who have Failed or Are Intolerant to Tyrosine Kinase Inhibitor Therapy (Protocol No. CGX-635-CML-203) Status: Ongoing

8.    A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine) (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation (Protocol No. CGX-635-CML-202) Status: Completed

9.   Neo-Adjuvant Docetaxel + Platinum for Locally Advanced Breast Cancer: A  single arm observational study (ICON/LABC/0108) Status: Discontinued.